Doxycycline and Rifampin — Competitive Intelligence Brief

Doxycycline and Rifampin (Doxycycline and Rifampin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

phase 3 Antibiotic combination Bacterial 30S ribosome (doxycycline); bacterial RNA polymerase (rifampin) Infectious Disease Small molecule

Target snapshot

Doxycycline and Rifampin (Doxycycline and Rifampin) — University of South Florida. Doxycycline and rifampin are a combination of two antibiotics that work synergistically to inhibit bacterial protein synthesis and RNA polymerase, respectively, to treat infections.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Doxycycline and Rifampin TARGET	Doxycycline and Rifampin	University of South Florida	phase 3	Antibiotic combination	Bacterial 30S ribosome (doxycycline); bacterial RNA polymerase (rifampin)
PPI-amoxicillin-clarithromycin	PPI-amoxicillin-clarithromycin	National Taiwan University Hospital	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome
Cefazolin + Gentamicin	Cefazolin + Gentamicin	Mercy Health Ohio	marketed	Beta-lactam antibiotic + aminoglycoside antibiotic combination	Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin)
BENZOYL PEROXIDE/ CLINDAMYCIN	BENZOYL PEROXIDE/ CLINDAMYCIN	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Vonoprazan + amoxicillin + clarithromycin	Vonoprazan + amoxicillin + clarithromycin	The Third Xiangya Hospital of Central South University	marketed	Proton pump inhibitor + antibiotic combination	H+ K+-ATPase (vonoprazan); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin)
Vonoprazan + amoxicillin	Vonoprazan + amoxicillin	The Third Xiangya Hospital of Central South University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class